Abstract | BACKGROUND: METHODS: 25 subjects with mild allergic asthma were randomized to oral roflumilast 500 mcg or placebo, once daily for 14 days in a double-blind, placebo-controlled, crossover study. Allergen challenge was performed on Day 14, and FEV1 was measured until 7 h post challenge. Methacholine challenge was performed on Days 1 (pre-dose), 13 (24 h pre- allergen), and 15 (24 h post- allergen), and sputum induction was performed on Days 1, 13, 14 (7 h post- allergen), and 15. RESULTS: CONCLUSIONS: This study demonstrates a protective effect of roflumilast on allergen-induced airway inflammation. The observed attenuation of sputum eosinophils and neutrophils demonstrates the anti-inflammatory properties of PDE4 inhibition and supports the roles of both cell types in the development of late phase bronchoconstriction and AHR. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01365533.
|
Authors | Gail M Gauvreau, Louis-Philippe Boulet, Christine Schmid-Wirlitsch, Johanne Côté, Mylinh Duong, Kieran J Killian, Joanne Milot, Francine Deschesnes, Tara Strinich, Richard M Watson, Dirk Bredenbröker, Paul M O'Byrne |
Journal | Respiratory research
(Respir Res)
Vol. 12
Pg. 140
(Oct 26 2011)
ISSN: 1465-993X [Electronic] England |
PMID | 22029856
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Allergens
- Aminopyridines
- Benzamides
- Cyclopropanes
- Phosphodiesterase 4 Inhibitors
- Roflumilast
|
Topics |
- Adolescent
- Adult
- Allergens
(toxicity)
- Aminopyridines
(therapeutic use)
- Asthma
(drug therapy, immunology, pathology)
- Benzamides
(therapeutic use)
- Cross-Over Studies
- Cyclopropanes
(therapeutic use)
- Double-Blind Method
- Female
- Forced Expiratory Volume
(drug effects, immunology)
- Humans
- Male
- Middle Aged
- Phosphodiesterase 4 Inhibitors
(therapeutic use)
- Pneumonia
(drug therapy, immunology, pathology)
- Pulmonary Eosinophilia
(chemically induced, immunology, pathology)
- Young Adult
|